Lincoln Capital Corp Purchased $201,000 in Hologic, Inc. (HOLX) Shares

Lincoln Capital Corp Purchased $201,000 in Hologic, Inc. (HOLX) Shares

Lincoln Capital Corp acquired a new position in Hologic, Inc. (NASDAQ:HOLX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,900 shares of the medical equipment provider’s stock, valued at approximately $201,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Parnassus Investments CA grew its holdings in Hologic by 3.4% during the 2nd quarter. Parnassus Investments CA now owns 16,241,334 shares of the medical equipment provider’s stock valued at $645,593,000 after buying an additional 535,745 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Hologic by 5.1% during the 2nd quarter. Victory Capital Management Inc. now owns 5,813,464 shares of the medical equipment provider’s stock valued at $231,085,000 after buying an additional 282,510 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Hologic by 15.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,301,792 shares of the medical equipment provider’s stock valued at $85,995,000 after buying an additional 301,278 shares in the last quarter. Partner Fund Management L.P. grew its holdings in Hologic by 20.3% during the 2nd quarter. Partner Fund Management L.P. now owns 1,892,703 shares of the medical equipment provider’s stock valued at $75,235,000 after buying an additional 319,846 shares in the last quarter. Finally, Guggenheim Capital LLC grew its holdings in Hologic by 4.7% during the 1st quarter. Guggenheim Capital LLC now owns 1,739,642 shares of the medical equipment provider’s stock valued at $64,993,000 after buying an additional 77,589 shares in the last quarter. 98.65% of the stock is owned by institutional investors.

A number of research firms have weighed in on HOLX. Needham & Company LLC lifted their target price on Hologic from $43.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, August 1st. BidaskClub raised Hologic from a “hold” rating to a “buy” rating in a report on Wednesday, August 1st. Deutsche Bank lifted their target price on Hologic from $42.00 to $45.00 and gave the company a “hold” rating in a report on Wednesday, August 1st. Zacks Investment Research raised Hologic from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Finally, Bank of America lifted their target price on Hologic from $44.00 to $47.00 and gave the company a “buy” rating in a report on Wednesday, August 1st. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $44.50.

In related news, Director Sally Crawford sold 13,257 shares of the business’s stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $39.54, for a total value of $524,181.78. Following the completion of the sale, the director now owns 167,701 shares in the company, valued at approximately $6,630,897.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Benjamin Jordan Cohn sold 3,437 shares of the business’s stock in a transaction that occurred on Wednesday, September 19th. The stock was sold at an average price of $41.50, for a total value of $142,635.50. Following the completion of the sale, the insider now owns 16,520 shares of the company’s stock, valued at approximately $685,580. The disclosure for this sale can be found here. Insiders have sold 47,661 shares of company stock valued at $1,927,174 in the last three months. 0.88% of the stock is owned by insiders.

Shares of NASDAQ HOLX opened at $41.35 on Wednesday. Hologic, Inc. has a 12 month low of $35.10 and a 12 month high of $45.09. The company has a quick ratio of 0.99, a current ratio of 1.29 and a debt-to-equity ratio of 1.12. The stock has a market cap of $11.15 billion, a PE ratio of 20.37, a price-to-earnings-growth ratio of 2.01 and a beta of 0.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Tuesday, July 31st. The medical equipment provider reported $0.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.02. Hologic had a positive return on equity of 22.18% and a negative net margin of 2.47%. The company had revenue of $824.00 million during the quarter, compared to analyst estimates of $800.14 million. Sell-side analysts anticipate that Hologic, Inc. will post 2.24 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Recommended Story: Risk Tolerance and Your Investment Decisions

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Related posts

Leave a Comment